SAN FRANCISCO and SUZHOU, China, Jan. 16, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic and other major…

Missoulian

Missoula

Missoula County

Montana

United States

Innovent and ASK Pharm Jointly Announce NMPA Approval of Limertinib, a Third-generation EGFR TKI for the Treatment of Lung Cancer

All Sides

Media Bias/Fact Check

Lee Enterprises

The Chandler Arizonan

Chandler

Maricopa County

Arizona

Queen Creek Tribune

Queen Creek

Innovent Biologics' third-gen EGFR TKI drug limertinib receives NMPA approval for T790M-mutated NSCLC, showing strong efficacy with 92.4% disease control rate.

stocktitan.net

Innovent's Limertinib Wins NMPA Approval for Lung Cancer with 68.8% Response Rate

Summary: A new demonstrates the high sensitivity of the NeXT Personal test for detecting ctDNA in early-stage lung cancer. Takeaways: 
Ultra-Sensitive Detection: NeXT Personal achieved high sensitivity in detecting ctDNA for early-stage non-small cell lung cancer (NSCLC), including 100% detection in non-adenocarcinomas and 81% in lung adenocarcinomas (LUAD), showcasing its effectiveness even for challenging subtypes. Prognostic Value: ctDNA leve…

Innovent and ASK Pharm Jointly Announce NMPA Approval of Limertinib, a Third-generation EGFR TKI for the Treatment of Lung Cancer

Coverage Details

Bias Distribution

Ownership

Similar News Topics

Similar News Topics